Background: Psoriatic Arthritis (PsA) is the most common extracutaneous manifestation of
psoriasis. This chronic inflammatory arthritis is burdened with significant morbidity, leading to irreversible
joint damage and disability. In recent years, a deeper understating of its pathogenesis has led
to the development of several new drugs targeting different pathways.
Objectives: This review aims to highlight the clinical efficacy and safety of the novel agents that have
become recently available for the treatment of PsA, as well as new promising therapeutic targets that
are being evaluated in clinical trials.
Methods: For the purpose of this narrative review, we searched in the MEDLINE and ClinicalTrials.
Results: After the introduction of the first biological drugs targeting Tumor Necrosis Factor (TNF),
several other drugs with different targets have been developed, including anti-Interleukin (IL)
12/23p40, anti-IL17, and, more recently, anti-IL23p19 agents.
Discussion: Data supporting the efficacy of different agents in the major domains of PsA, as well as
their safety issues, are summarized here. Finally, the current pipeline, including several novel nonbiological
small molecules, such as Janus kinase (JAK) inhibitors, that are currently being evaluated in
clinical trials are also presented.
Conclusion: The availability of newer therapeutic agents has substantially changed the treatment strategy
for PsA. In the future, a personalized treatment approach will probably achieve better control of